CAP-53194

• Description :

  CAP-53194 is a selective Plk1 inhibitor with potential anticancer activity. CAP-53194 was identified by a high-throughput virtual screening approach using molecular docking, showing 100-fold selectivity for Plk1 over Plk2-4 and other cell cycle kinases. CAP-53194 is able to effectively exploit subtle differences between the binding sites of Plk1 and other Ser/Thr kinases, thereby enhancing their inhibitory effects. CAP-53194 meets the Lipinski compound analog criteria and passes other ADMET filters, indicating good compound compatibility. CAP-53194 belongs to a new class of potential Plk1 inhibitors suitable for subsequent compound development and testing[1].

• UNSPSC :

  12352005

• Target :

  Polo-like Kinase (PLK)

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cap-53194.html

• Smiles :

  O=C(NC1=CC=C(C=C1)[N+]([O-])=O)C2=C(N(N=N2)C3=CC=C(C=C3)[N+]([O-])=O)C4=CC=CC=C4

• Molecular Formula :

  C21H14N6O5

• Molecular Weight :

  430.37

• References & Citations :

  [1]Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [660817-08-3]